Login to Your Account

Fibrotech launches diabetic nephropathy study, partnering talks

By Nuala Moran
Staff Writer

Friday, March 21, 2014
LONDON – Fibrotech Therapeutics Pty has begun dosing in the phase Ib trial of its lead molecule FT011 in treating diabetic nephropathy and is now involved in “intensive discussions” to partner the small-molecule antifibrotic.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription